View Future GrowthSunshine Biopharma 過去の業績過去 基準チェック /06Sunshine Biopharmaは16.2%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで33.8%毎年増加している。売上は成長しており、年平均53.5%の割合である。主要情報16.18%収益成長率160.38%EPS成長率Biotechs 業界の成長17.04%収益成長率53.54%株主資本利益率-28.07%ネット・マージン-17.02%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Mar 31Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$0.18 loss per share (improved from US$1.76 loss in FY 2022). Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed 83% from FY 2022). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: US$0.025 loss per share (improved from US$0.077 loss in 3Q 2022). Revenue: US$5.96m (up US$5.82m from 3Q 2022). Net loss: US$651.5k (loss narrowed 55% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.036 loss per share (further deteriorated from US$0.034 loss in 2Q 2022). Revenue: US$5.56m (up US$5.41m from 2Q 2022). Net loss: US$902.1k (loss widened 67% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 75%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.Reported Earnings • May 11First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)First quarter 2023 results: US$0.077 loss per share. Revenue: US$4.89m (up US$4.77m from 1Q 2022). Net loss: US$1.70m (loss widened 38% from 1Q 2022).Reported Earnings • Apr 08Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)Full year 2022 results: US$1.76 loss per share. Revenue: US$4.35m (up US$4.12m from FY 2021). Net loss: US$26.7m (loss widened 115% from FY 2021).Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)Third quarter 2022 results: US$0.077 loss per share (improved from US$1.59 loss in 3Q 2021). Net loss: US$1.46m (loss narrowed 64% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.すべての更新を表示Recent updatesお知らせ • May 20Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million.Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 11,160,000 Price\Range: $0.5 Discount Per Security: $0.035 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 840,000 Price\Range: $0.49999 Discount Per Security: $0.03499お知らせ • Apr 01Sunshine Biopharma, Inc. announced delayed annual 10-K filingOn 03/31/2026, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Feb 06Sunshine Biopharma Inc. Announces Resignation of Abderrazzak Merzouki as Chief Operating Officer, Effective from February 5, 2026Sunshine Biopharma Inc. announced that Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective from February 5, 2026.お知らせ • Oct 24Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025.お知らせ • Aug 05Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million.Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,577,965 Price\Range: $2.07お知らせ • Apr 03+ 1 more updateSunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.459994 million.Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.459994 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 928,404 Price\Range: $2.07 Discount Per Security: $0.1656 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 260,000 Price\Range: $2.06999 Discount Per Security: $0.165599 Transaction Features: Registered Direct Offeringお知らせ • Apr 01Sunshine Biopharma, Inc. announced delayed annual 10-K filingOn 03/31/2025, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 15Sunshine Biopharma, Inc. Appoints Michel Roy as Its New Chief Commercial OfficerSunshine Biopharma Inc. announced the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives. In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutical industry, Mr. Roy has held various leadership positions at major international pharmaceutical companies, where he successfully led teams to achieve significant revenue growth and market expansion. From 2020 to 2024, Mr. Roy founded and led the Canadian operations of Shilpa Medicare Ltd., a prominent pharmaceutical company based in Raichur, Karnataka, India. Shilpa specializes in manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations, with a strong presence in oncology APIs, drug delivery systems, peptides, and specialty chemicals. Previously, from 2014 to 2020, Mr. Roy was Vice President, Business Development and Sales for Intas Pharmaceuticals Ltd., a major pharmaceutical company with a strong presence in over 85 countries. Intas is headquartered in Ahmedabad, India. While at Intas, Mr. Roy was responsible for the strategic planning, business development, sales, financial management and regulatory affairs. At the beginning of his career, Mr. Roy worked as a consultant for various international Contract Research Organization (CRO) companies. Mr. Roy is a results-driven professional with considerable business development experience in the pharmaceutical and biotechnology sectors including licensing, sales, regulatory affairs, operations and program management. His strong negotiation and communication skills, coupled with an in-depth knowledge of all facets of the drug development process contribute to a stellar reputation as a dynamic leader who produces superior results. Mr. Roy received his Executive Master of Business Administration (EMBA) from John Molson School of Business (Concordia University) in 2010 and his Master of Science (M.Sc.) from Université de Montréal in 1999. He also received a Bachelor of Commerce degree with a major in economics from Concordia University in 1990.お知らせ • Dec 10Sunshine Biopharma Inc. Announces Novel Inhibitor for SARS CoronavirusSunshine Biopharma Inc. announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-1 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV- 2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent rapid disease progression and reduce hospitalization. PLpro is an alternative therapeutic target for developing antiviral compounds against proteolytic processing activity of SARS-CoV- two. PLpro is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection, leading to a more severe disease outcome. In August 2024, Sunshine Biopharma published initial research results on its PLpro inhibitors library in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, Sunshine Biopharma's current lead compound was recently found to be active at sub-micromolar concentrations against PLpro and exhibited antiviral activity in SRAS-CoV-2 infected cells as well as in cells infected with several different VOC. In addition, the Company's lead compound had favorable pharmacokinetics properties inrod species and exhibited preferred drug accumulation in the lungs over plasma. The compound was found to beally active in a K18-human-ACE2 transgenic mouse model and to significantly reduce virus load in the lungs of infected animals in a dose-dependent manner without gross toxicities. This research is being carried out in collaboration with the University of Arizona.お知らせ • Dec 02Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular CarcinomaSunshine Biopharma Inc. announced that it has completed mouse model studies providing proof-of-concept for the Company's K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several systematic treatment options were available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%. When transfected into cultured human HCC cell lines and patient-derived HCC cells, K1.1 mRNA exhibited dose-dependent anti-proliferative activity in vitro. Following encapsulation in specifically engineered lipids, the resulting K1.1 mRNA-Lipid Nanoparticles (K1.1/LNP) were efficiently delivered to livers of mice in a dose-dependent manner in vivo. K1.1/LNP, under repeated systemic dosing, was found to reduce growth of two different types of human HCC tumors orthotopically grafted into the livers of immunodeficient mice. The pharmacodynamics of K1.1/LNP in intrahepatic tumors was well correlated with antitumor efficacy in mice.お知らせ • Oct 18Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024.お知らせ • Sep 05Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal ChemistrySunshine Biopharma, Inc. announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection. There are still unmet medical needs to combat SARS-CoV-2 infection. SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent disease rapid progression and reduce hospitalization. PLpro is a compelling therapeutic target for developing antiviral compounds against SARS-CoV-2. It is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection by the virus. The active site of an enzyme is almost always the primary target for drug design. PLpro eluded scientist for many years due to its featureless active site. To address the challenge of PLpro's indistinct active site, designed and synthesized a noncovalent inhibitor library targeting a vulnerability in PLpro remote from the active site incorporating the "BL2-groove", a key feature discovered by project co-lead, Prof. Rui Xiong of the University of Arizona. One of the 50 compounds, XR8-23 (Compound 10), had an enzyme inhibition activity (IC50) of 0.39 µM and exhibited a broad spectrum of antiviral activity towards at least 4 strains of VOC including WA1/2020, Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1). It had over 10-fold of selective accumulation in the lungs than in plasma and exhibited in vivo activity in a mouse-adapted SARS-CoV-2 infection (MA10) at 10 mg/kg by repeated IV injections.お知らせ • Aug 15Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 08/14/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 07Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued ListingSunshine Biopharma, Inc. announced a one for twenty reverse split of its common stock, effective at market open on August 8, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.お知らせ • Jun 08Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101On June 7, 2024, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’), that based on further review of the Company’s public filings with the Securities and Exchange Commission and supporting materials submitted to Nasdaq, its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the ‘alternative cashless exercise’ provision of the Series A warrants the Company issued on February 15, 2024, raises public interest and investor protection concerns because the issuance of Series A warrants resulted in substantial dilution for the stockholders of the Company to date and may cause potential future dilution. Accordingly, as set forth in the letter, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. As set forth in the letter, under the ‘alternative cashless exercise’ provision set forth in Section 2.3 of the Series A warrants the holder of the Series A warrant, has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise of the Series A warrant and (y) 2. However, this multiplier was not proportionally adjusted to 0.02 in connection with the 1-for-100 reverse stock split the Company implemented on April 17, 2024, but instead it remained unchanged at 2. As set forth in the letter, a reverse stock split has the effect of increasing the stock price by proportionally consolidating the outstanding shares; however, the number of shares issuable to Series A warrant holders under the ‘alternative cashless exercise’ provision were not so consolidated. As such, shareholders of the Company were substantially diluted, while the holders of the Series A warrants were enriched one-hundred fold. Moreover, in the event the Company effects another reverse stock split, the shareholders of the Company will be diluted even further to the benefit of the Series A warrant holders. For these reasons, in order to protect investors and the public interest, Nasdaq Rule 5101 empowers Nasdaq to apply additional and more stringent criteria for the continued listing of securities, or to suspend or delist particular securities, based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. The letter has no immediate effect on the listing of the Company’s common stock. The letter serves as a formal notification that the Nasdaq Hearings Panel (the ‘Panel’) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market. In that regard, the letter states that the Company should present its views with respect to this additional deficiency to the Panel in writing no later than June 14, 2024.お知らせ • May 17Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 05/15/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Mar 31Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$0.18 loss per share (improved from US$1.76 loss in FY 2022). Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed 83% from FY 2022). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.分析記事 • Mar 14Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching RevenuesSunshine Biopharma, Inc. ( NASDAQ:SBFM ) shareholders that were waiting for something to happen have been dealt a blow...お知らせ • Mar 04Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price RequirementAs previously disclosed, on March 24, 2023, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the ‘Minimum Bid Price Requirement’). On September 21, 2023, the Company received another notification letter from Nasdaq advising that Nasdaq’s staff had determined that the Company was eligible for an extension of an additional 180 calendar day period, or until March 18, 2024, to cure the bid price deficiency. On February 28, 2024, the Company received a notification letter from Nasdaq advising that Nasdaq’s staff had determined that as of February 27, 2024, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the ‘Low Priced Stocks Rule’). Accordingly, Nasdaq determined to remove the Company’s securities from listing and registration on The Nasdaq Stock Market, subject to the procedures set in the Nasdaq Listing Rule 5800 Series which provide the Company with the opportunity to appeal this determination. If the Company failed to file such appeal by March 6, 2024, trading of the Company’s common stock would be suspended at the opening of business on March 8, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the ‘SEC’), which would remove the Company’s securities from listing and registration on The Nasdaq Stock Market. On February 28, 2024, the Company submitted such appeal, and a hearing has been scheduled for April 25, 2024. Accordingly, the delisting action referenced in the Nasdaq staff’s determination letter has been stayed, pending a final written decision by the Nasdaq Hearings Panel. The Company has received shareholder approval for and intends to effect a 40-for-1 reverse stock split 20 days after the mailing of its definitive information statement (the preliminary form of which was filed with the SEC on February 21, 2024) to shareholders, to regain compliance with the Minimum Bid Price Requirement. There is no assurance the Company will regain compliance with the Minimum Bid Price Requirement.New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 141% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Market cap is less than US$10m (US$3.46m market cap).New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (340% increase in shares outstanding). Market cap is less than US$10m (US$6.84m market cap).お知らせ • Jan 31Sunshine Biopharma, Inc. Announces Executive ChangesOn January 25, 2024, the Board of Directors of Sunshine Biopharma, Inc. held its annual meeting. At the meeting the company elected Dr. Abderrazzak Merzouki as Chief Science Officer, Mr. Marc Beaudoin as Chief Operating Officer, and Mr. Malek Chamoun as Chief Development Officer. Previously, Dr. Merzouki had held the position of Chief Operating Officer. Mr. Beaudoin and Mr. Chamoun are new officers. The other officers are continuing in their prior positions. Mr. Chamoun is also currently President of the Company’s wholly owned subsidiary, Nora Pharma Inc. The resumes of the Company’s new officers are as follows: Malek Chamoun, age 39,was appointed as Chief Development Officer in January 2024. In 2017 he founded Nora Pharma Inc., a Canadian pharmaceutical company (“Nora Pharma”), based in Montreal, where he has been the President and CEO since inception. The company acquired Nora Phara in October 2022. Mr. Chamoun received a bachelor’s degree in business administration from Hautes Études Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012. He devotes all of his business time to Nora’s affairs. Marc Beaudoin, age 57, was appointed as Chief Operating Officer in January 2024. Mr. Beaudoin has been self-employed as a business strategy consultant, primarily in the pharmaceutical and biopharmaceutical sectors, since 2016. From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and Communications, Strategic Planning, Business Development & Portfolio Management. As an executive and an entrepreneur, he combines expertise in strategic planning with operational and commercial execution. Mr. Beaudoin obtained his MBA from Sherbrooke University in 2018. He also holds multiple certifications (including a fellowship) from the Association for Supply Chain Management.分析記事 • Jan 29Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.3x Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) may be sending very bullish...Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: US$0.025 loss per share (improved from US$0.077 loss in 3Q 2022). Revenue: US$5.96m (up US$5.82m from 3Q 2022). Net loss: US$651.5k (loss narrowed 55% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • Oct 19Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect five persons to Board of Directors, until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to consider and ratify the appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accountant to audit the Company’s financial books and records for its fiscal year ending December 31, 2023; to consider and approve the Company’s 2023 Equity Incentive Plan.お知らせ • Sep 23Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid ComplianceSunshine Biopharma Inc. (the "Company") announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. The Nasdaq staff has determined that Sunshine Biopharma is eligible, based on the Company meeting the continued listing requirements for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time before March 18, 2024, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "SBFM".分析記事 • Sep 12Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A CatchUnfortunately for some shareholders, the Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) share price has dived 26% in the last...Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.036 loss per share (further deteriorated from US$0.034 loss in 2Q 2022). Revenue: US$5.56m (up US$5.41m from 2Q 2022). Net loss: US$902.1k (loss widened 67% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 75%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.お知らせ • May 17Sunshine Biopharma, Inc. announced that it has received CAD 5 million in fundingOn May 16, 2023, Sunshine Biopharma, Inc. closed the transaction. In connection with the sale of the securities described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder for transactions not involving a public offering.Reported Earnings • May 11First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)First quarter 2023 results: US$0.077 loss per share. Revenue: US$4.89m (up US$4.77m from 1Q 2022). Net loss: US$1.70m (loss widened 38% from 1Q 2022).Reported Earnings • Apr 08Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)Full year 2022 results: US$1.76 loss per share. Revenue: US$4.35m (up US$4.12m from FY 2021). Net loss: US$26.7m (loss widened 115% from FY 2021).お知らせ • Jan 20Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces a share repurchase program. Under the program, the company will repurchase up to $2 million worth of its shares. As of November 7, 2022, the company had approximately 22,600,000 shares of common stock issued and outstanding.Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)Third quarter 2022 results: US$0.077 loss per share (improved from US$1.59 loss in 3Q 2021). Net loss: US$1.46m (loss narrowed 64% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.Seeking Alpha • Oct 20Sunshine Biopharma acquires Nora Pharma for C$30MSunshine Biopharma (NASDAQ:SBFM) said on Thursday it had completed the acquisition of all the outstanding shares of Nora Pharma for C$30M ($21.9M). The acquisition will help Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma will operate as a subsidiary of Sunshine. (SBFM) is down ~4% premarket.分析記事 • Aug 08We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)Second quarter 2022 results: US$0.034 loss per share (up from US$1.20 loss in 2Q 2021). Net loss: US$538.9k (loss narrowed 81% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.Seeking Alpha • Aug 04Sunshine Biopharma reports 1H resultsSunshine Biopharma press release (NASDAQ:SBFM): 1H Revenue of $0.27M. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021.Reported Earnings • May 07First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)First quarter 2022 results: US$0.23 loss per share (up from US$2.82 loss in 1Q 2021). Net loss: US$1.24m (loss narrowed 80% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.Seeking Alpha • Apr 17Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral DrugsSunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in with the CEO. The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement. Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.Board Change • Feb 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Rabi Kiderchah was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Feb 16Sunshine Biopharma Common Stock Deleted from Other OTCSunshine Biopharma, Inc. Common Stock has been deleted from Other OTC effective from February 15, 2022, due to Market Center Change Listed on NASDAQ.お知らせ • Jun 10Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as PlannedSunshine Biopharma Inc. confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned. The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death. Should these studies prove successful, the Company plans to file the data with the FDA and request authorization to do testing in actual COVID-19 patients. Sunshine Biopharma’s protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.お知らせ • May 26Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer TypesSunshine Biopharma Inc. announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply. Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity. Among these are the vinca alkaloids (vinblastine and vincristine), the taxanes (paclitaxel and docetaxel), the anthracyclines (doxorubicin and daunorubicin), the topoisomerase inhibitors (topotecan and etoposide), and the tyrosine kinase inhibitors (dasatinib and gefitinib). Sunshine Biopharma’s P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs. In addition, it has been recognized that most cancers consist of a heterogeneous population of drug-sensitive and drug-resistant cells. During the course of current chemotherapy regiments, drug-sensitive cells are selectively destroyed and resistant cells become the dominant cancer cell population, leading to recurrence and metastasis. Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated.お知らせ • Apr 24Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.Sunshine Biopharma, Inc. (OTCPK:SBFM) announced that it has received $500,000 in a round funding from returning investor RB Capital Partners, Inc. on April 22, 2021.お知らせ • Mar 06Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC TestingSunshine Biopharma Inc. announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies.お知らせ • Aug 15Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 08/14/2020, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.収支内訳Sunshine Biopharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqCM:SBFM 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2635-615031 Dec 2536-615130 Sep 2537-616130 Jun 2536-616131 Mar 2536-515131 Dec 2435-515130 Sep 2433-413230 Jun 2430-412231 Mar 2427-411231 Dec 2324-511230 Sep 2320-2714130 Jun 2315-2813131 Mar 239-2712131 Dec 224-279130 Sep 220-33130 Jun 220-52131 Mar 220-72131 Dec 210-122130 Sep 210-142130 Jun 210-112031 Mar 210-92031 Dec 200-31030 Sep 200-21030 Jun 200-21031 Mar 200-11031 Dec 190-11030 Sep 190-10030 Jun 190-21031 Mar 190-21031 Dec 180-21030 Sep 180-21030 Jun 180-11031 Mar 180-11031 Dec 170-11030 Sep 170-21030 Jun 170-31031 Mar 170-31031 Dec 160-31030 Sep 160-31030 Jun 160-21031 Mar 160-20031 Dec 150-20030 Sep 150-11030 Jun 150-110質の高い収益: SBFMは現在利益が出ていません。利益率の向上: SBFMは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: SBFMは利益を出していないが、過去 5 年間で年間16.2%の割合で損失を削減してきた。成長の加速: SBFMの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: SBFMは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 43% ) と比較することは困難です。株主資本利益率高いROE: SBFMは現在利益が出ていないため、自己資本利益率 ( -28.07% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 01:30終値2026/05/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Sunshine Biopharma, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関David BoucheyAegis Capital Corporation
Reported Earnings • Mar 31Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$0.18 loss per share (improved from US$1.76 loss in FY 2022). Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed 83% from FY 2022). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.
Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: US$0.025 loss per share (improved from US$0.077 loss in 3Q 2022). Revenue: US$5.96m (up US$5.82m from 3Q 2022). Net loss: US$651.5k (loss narrowed 55% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.036 loss per share (further deteriorated from US$0.034 loss in 2Q 2022). Revenue: US$5.56m (up US$5.41m from 2Q 2022). Net loss: US$902.1k (loss widened 67% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 75%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
Reported Earnings • May 11First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)First quarter 2023 results: US$0.077 loss per share. Revenue: US$4.89m (up US$4.77m from 1Q 2022). Net loss: US$1.70m (loss widened 38% from 1Q 2022).
Reported Earnings • Apr 08Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)Full year 2022 results: US$1.76 loss per share. Revenue: US$4.35m (up US$4.12m from FY 2021). Net loss: US$26.7m (loss widened 115% from FY 2021).
Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)Third quarter 2022 results: US$0.077 loss per share (improved from US$1.59 loss in 3Q 2021). Net loss: US$1.46m (loss narrowed 64% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
お知らせ • May 20Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million.Sunshine Biopharma, Inc. has completed a Composite Units Offering in the amount of $6 million. Security Name: Common Units Security Type: Equity/Derivative Unit Securities Offered: 11,160,000 Price\Range: $0.5 Discount Per Security: $0.035 Security Name: Pre-Funded Units Security Type: Equity/Derivative Unit Securities Offered: 840,000 Price\Range: $0.49999 Discount Per Security: $0.03499
お知らせ • Apr 01Sunshine Biopharma, Inc. announced delayed annual 10-K filingOn 03/31/2026, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Feb 06Sunshine Biopharma Inc. Announces Resignation of Abderrazzak Merzouki as Chief Operating Officer, Effective from February 5, 2026Sunshine Biopharma Inc. announced that Dr. Abderrazzak Merzouki resigned as chief operating officer of Sunshine Biopharma Inc., effective from February 5, 2026.
お知らせ • Oct 24Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025Sunshine Biopharma, Inc., Annual General Meeting, Dec 11, 2025.
お知らせ • Aug 05Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million.Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $32.246388 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 15,577,965 Price\Range: $2.07
お知らせ • Apr 03+ 1 more updateSunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.459994 million.Sunshine Biopharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.459994 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 928,404 Price\Range: $2.07 Discount Per Security: $0.1656 Security Name: Pre-Funded Warrants Security Type: Equity Warrant Securities Offered: 260,000 Price\Range: $2.06999 Discount Per Security: $0.165599 Transaction Features: Registered Direct Offering
お知らせ • Apr 01Sunshine Biopharma, Inc. announced delayed annual 10-K filingOn 03/31/2025, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 15Sunshine Biopharma, Inc. Appoints Michel Roy as Its New Chief Commercial OfficerSunshine Biopharma Inc. announced the appointment of Mr. Michel Roy as its new Chief Commercial Officer (CCO), effective immediately. Mr. Roy brings a wealth of experience and a proven track record of success in driving commercial growth and strategic initiatives. In this role, Mr. Roy will be responsible for overseeing the Company's commercial strategy, including sales, marketing, and business development. With over 20 years of experience in the pharmaceutical industry, Mr. Roy has held various leadership positions at major international pharmaceutical companies, where he successfully led teams to achieve significant revenue growth and market expansion. From 2020 to 2024, Mr. Roy founded and led the Canadian operations of Shilpa Medicare Ltd., a prominent pharmaceutical company based in Raichur, Karnataka, India. Shilpa specializes in manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations, with a strong presence in oncology APIs, drug delivery systems, peptides, and specialty chemicals. Previously, from 2014 to 2020, Mr. Roy was Vice President, Business Development and Sales for Intas Pharmaceuticals Ltd., a major pharmaceutical company with a strong presence in over 85 countries. Intas is headquartered in Ahmedabad, India. While at Intas, Mr. Roy was responsible for the strategic planning, business development, sales, financial management and regulatory affairs. At the beginning of his career, Mr. Roy worked as a consultant for various international Contract Research Organization (CRO) companies. Mr. Roy is a results-driven professional with considerable business development experience in the pharmaceutical and biotechnology sectors including licensing, sales, regulatory affairs, operations and program management. His strong negotiation and communication skills, coupled with an in-depth knowledge of all facets of the drug development process contribute to a stellar reputation as a dynamic leader who produces superior results. Mr. Roy received his Executive Master of Business Administration (EMBA) from John Molson School of Business (Concordia University) in 2010 and his Master of Science (M.Sc.) from Université de Montréal in 1999. He also received a Bachelor of Commerce degree with a major in economics from Concordia University in 1990.
お知らせ • Dec 10Sunshine Biopharma Inc. Announces Novel Inhibitor for SARS CoronavirusSunshine Biopharma Inc. announced that it has developed an orally active protease inhibitor with dose-dependent antiviral activity in mice infected with SARS Coronavirus (SARS-CoV-2). There are still unmet medical needs for agents to combat SARS-CoV-2 infections. SARS-CoV-1 is the etiologic agent of COVID-19 and one of three types of Coronavirus that cause Severe Acute Respiratory Syndrome (SARS). SARS-CoV- 2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent rapid disease progression and reduce hospitalization. PLpro is an alternative therapeutic target for developing antiviral compounds against proteolytic processing activity of SARS-CoV- two. PLpro is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection, leading to a more severe disease outcome. In August 2024, Sunshine Biopharma published initial research results on its PLpro inhibitors library in the Journal of Medicinal Chemistry (J. Med. Chem. 2024, Sunshine Biopharma's current lead compound was recently found to be active at sub-micromolar concentrations against PLpro and exhibited antiviral activity in SRAS-CoV-2 infected cells as well as in cells infected with several different VOC. In addition, the Company's lead compound had favorable pharmacokinetics properties inrod species and exhibited preferred drug accumulation in the lungs over plasma. The compound was found to beally active in a K18-human-ACE2 transgenic mouse model and to significantly reduce virus load in the lungs of infected animals in a dose-dependent manner without gross toxicities. This research is being carried out in collaboration with the University of Arizona.
お知らせ • Dec 02Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular CarcinomaSunshine Biopharma Inc. announced that it has completed mouse model studies providing proof-of-concept for the Company's K1.1 mRNA product as a novel therapeutic agent for human hepatocellular carcinoma. Human hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide and the most common type of primary liver cancers in adults. In recent years, several systematic treatment options were available to HCC patients either as first-line or second-line treatment. Yet, the five-year survival rate of HCC patients remains at only 18-21%. When transfected into cultured human HCC cell lines and patient-derived HCC cells, K1.1 mRNA exhibited dose-dependent anti-proliferative activity in vitro. Following encapsulation in specifically engineered lipids, the resulting K1.1 mRNA-Lipid Nanoparticles (K1.1/LNP) were efficiently delivered to livers of mice in a dose-dependent manner in vivo. K1.1/LNP, under repeated systemic dosing, was found to reduce growth of two different types of human HCC tumors orthotopically grafted into the livers of immunodeficient mice. The pharmacodynamics of K1.1/LNP in intrahepatic tumors was well correlated with antitumor efficacy in mice.
お知らせ • Oct 18Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024Sunshine Biopharma, Inc., Annual General Meeting, Dec 10, 2024.
お知らせ • Sep 05Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal ChemistrySunshine Biopharma, Inc. announced the publication of new research results in the Journal of Medicinal Chemistry. The published data demonstrate a novel PLpro inhibitor with submicromolar potency and in vivo efficacy in a mouse model of SARS-CoV-2 infection. This peer-reviewed study marks an important milestone for Sunshine Biopharma in its effort to develop an effective treatment for SARS-CoV-2 infection. There are still unmet medical needs to combat SARS-CoV-2 infection. SARS-CoV-2 undergoes mutation at a rapid rate, which leads to the continuous emergence of variants of concern (VOC) posing a significant threat to public health. In addition, certain populations, such as immunocompromised patients who are susceptible to severe and prolonged infections, may not respond well to current therapies or vaccines. For high-risk patients, blocking early infection at home may prevent disease rapid progression and reduce hospitalization. PLpro is a compelling therapeutic target for developing antiviral compounds against SARS-CoV-2. It is a virus encoded protease essential for viral replication and is responsible for suppression of the human immune system following infection by the virus. The active site of an enzyme is almost always the primary target for drug design. PLpro eluded scientist for many years due to its featureless active site. To address the challenge of PLpro's indistinct active site, designed and synthesized a noncovalent inhibitor library targeting a vulnerability in PLpro remote from the active site incorporating the "BL2-groove", a key feature discovered by project co-lead, Prof. Rui Xiong of the University of Arizona. One of the 50 compounds, XR8-23 (Compound 10), had an enzyme inhibition activity (IC50) of 0.39 µM and exhibited a broad spectrum of antiviral activity towards at least 4 strains of VOC including WA1/2020, Gamma (P.1), Delta (B.1.617.2), and Omicron (BA.1). It had over 10-fold of selective accumulation in the lungs than in plasma and exhibited in vivo activity in a mouse-adapted SARS-CoV-2 infection (MA10) at 10 mg/kg by repeated IV injections.
お知らせ • Aug 15Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 08/14/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 07Sunshine Biopharma Announces Reverse Stock Split to Regain Compliance with Nasdaq's Minimum Bid Price Requirement for Continued ListingSunshine Biopharma, Inc. announced a one for twenty reverse split of its common stock, effective at market open on August 8, 2024. The reverse stock split was undertaken to regain compliance with Nasdaq's minimum bid price requirement for continued listing.
お知らせ • Jun 08Nasdaq Staff Determines to Delist Sunshine Biopharma's Securities Pursuant to its Discretionary Authority Under Listing Rule 5101On June 7, 2024, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’), that based on further review of the Company’s public filings with the Securities and Exchange Commission and supporting materials submitted to Nasdaq, its staff has determined to delist the Company’s securities pursuant to its discretionary authority under Listing Rule 5101. Specifically, as set forth in the letter, Nasdaq’s staff determined that the ‘alternative cashless exercise’ provision of the Series A warrants the Company issued on February 15, 2024, raises public interest and investor protection concerns because the issuance of Series A warrants resulted in substantial dilution for the stockholders of the Company to date and may cause potential future dilution. Accordingly, as set forth in the letter, this matter serves as an additional basis for delisting the Company’s securities from The Nasdaq Stock Market. As set forth in the letter, under the ‘alternative cashless exercise’ provision set forth in Section 2.3 of the Series A warrants the holder of the Series A warrant, has the right to receive an aggregate number of shares equal to the product of (x) the aggregate number of shares of common stock that would be issuable upon a cash exercise of the Series A warrant and (y) 2. However, this multiplier was not proportionally adjusted to 0.02 in connection with the 1-for-100 reverse stock split the Company implemented on April 17, 2024, but instead it remained unchanged at 2. As set forth in the letter, a reverse stock split has the effect of increasing the stock price by proportionally consolidating the outstanding shares; however, the number of shares issuable to Series A warrant holders under the ‘alternative cashless exercise’ provision were not so consolidated. As such, shareholders of the Company were substantially diluted, while the holders of the Series A warrants were enriched one-hundred fold. Moreover, in the event the Company effects another reverse stock split, the shareholders of the Company will be diluted even further to the benefit of the Series A warrant holders. For these reasons, in order to protect investors and the public interest, Nasdaq Rule 5101 empowers Nasdaq to apply additional and more stringent criteria for the continued listing of securities, or to suspend or delist particular securities, based on any event, condition, or circumstance that exists or occurs that makes initial or continued listing of the securities on Nasdaq inadvisable or unwarranted in the opinion of Nasdaq, even though the securities meet all enumerated criteria for initial or continued listing on Nasdaq. The letter has no immediate effect on the listing of the Company’s common stock. The letter serves as a formal notification that the Nasdaq Hearings Panel (the ‘Panel’) will consider this matter in their decision regarding the Company’s continued listing on The Nasdaq Capital Market. In that regard, the letter states that the Company should present its views with respect to this additional deficiency to the Panel in writing no later than June 14, 2024.
お知らせ • May 17Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 05/15/2024, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Mar 31Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFull year 2023 results: US$0.18 loss per share (improved from US$1.76 loss in FY 2022). Revenue: US$24.1m (up 454% from FY 2022). Net loss: US$4.51m (loss narrowed 83% from FY 2022). Revenue exceeded analyst estimates by 7.0%. Earnings per share (EPS) missed analyst estimates by 19%. Revenue is forecast to grow 68% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in the US.
分析記事 • Mar 14Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) 73% Dip In Price Shows Sentiment Is Matching RevenuesSunshine Biopharma, Inc. ( NASDAQ:SBFM ) shareholders that were waiting for something to happen have been dealt a blow...
お知らせ • Mar 04Sunshine Biopharma Announces Update on Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price RequirementAs previously disclosed, on March 24, 2023, Sunshine Biopharma, Inc. (the ‘Company’) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (‘Nasdaq’) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the ‘Minimum Bid Price Requirement’). On September 21, 2023, the Company received another notification letter from Nasdaq advising that Nasdaq’s staff had determined that the Company was eligible for an extension of an additional 180 calendar day period, or until March 18, 2024, to cure the bid price deficiency. On February 28, 2024, the Company received a notification letter from Nasdaq advising that Nasdaq’s staff had determined that as of February 27, 2024, the Company’s common stock had a closing bid price of $0.10 or less for ten consecutive trading days and accordingly, the Company was subject to the provisions contemplated under Listing Rule 5810(c)(3)(A)(iii) (the ‘Low Priced Stocks Rule’). Accordingly, Nasdaq determined to remove the Company’s securities from listing and registration on The Nasdaq Stock Market, subject to the procedures set in the Nasdaq Listing Rule 5800 Series which provide the Company with the opportunity to appeal this determination. If the Company failed to file such appeal by March 6, 2024, trading of the Company’s common stock would be suspended at the opening of business on March 8, 2024, and a Form 25-NSE would be filed with the Securities and Exchange Commission (the ‘SEC’), which would remove the Company’s securities from listing and registration on The Nasdaq Stock Market. On February 28, 2024, the Company submitted such appeal, and a hearing has been scheduled for April 25, 2024. Accordingly, the delisting action referenced in the Nasdaq staff’s determination letter has been stayed, pending a final written decision by the Nasdaq Hearings Panel. The Company has received shareholder approval for and intends to effect a 40-for-1 reverse stock split 20 days after the mailing of its definitive information statement (the preliminary form of which was filed with the SEC on February 21, 2024) to shareholders, to regain compliance with the Minimum Bid Price Requirement. There is no assurance the Company will regain compliance with the Minimum Bid Price Requirement.
New Risk • Feb 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 141% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (141% increase in shares outstanding). Market cap is less than US$10m (US$3.46m market cap).
New Risk • Feb 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 22% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (22% average weekly change). Shareholders have been substantially diluted in the past year (340% increase in shares outstanding). Market cap is less than US$10m (US$6.84m market cap).
お知らせ • Jan 31Sunshine Biopharma, Inc. Announces Executive ChangesOn January 25, 2024, the Board of Directors of Sunshine Biopharma, Inc. held its annual meeting. At the meeting the company elected Dr. Abderrazzak Merzouki as Chief Science Officer, Mr. Marc Beaudoin as Chief Operating Officer, and Mr. Malek Chamoun as Chief Development Officer. Previously, Dr. Merzouki had held the position of Chief Operating Officer. Mr. Beaudoin and Mr. Chamoun are new officers. The other officers are continuing in their prior positions. Mr. Chamoun is also currently President of the Company’s wholly owned subsidiary, Nora Pharma Inc. The resumes of the Company’s new officers are as follows: Malek Chamoun, age 39,was appointed as Chief Development Officer in January 2024. In 2017 he founded Nora Pharma Inc., a Canadian pharmaceutical company (“Nora Pharma”), based in Montreal, where he has been the President and CEO since inception. The company acquired Nora Phara in October 2022. Mr. Chamoun received a bachelor’s degree in business administration from Hautes Études Commerciales, Montreal, Quebec, Canada in 2008 and became a licensed CPA in Canada in 2012. He devotes all of his business time to Nora’s affairs. Marc Beaudoin, age 57, was appointed as Chief Operating Officer in January 2024. Mr. Beaudoin has been self-employed as a business strategy consultant, primarily in the pharmaceutical and biopharmaceutical sectors, since 2016. From 2006 to 2016, he held several executive positions at Sandoz Canada in various areas including Marketing and Communications, Strategic Planning, Business Development & Portfolio Management. As an executive and an entrepreneur, he combines expertise in strategic planning with operational and commercial execution. Mr. Beaudoin obtained his MBA from Sherbrooke University in 2018. He also holds multiple certifications (including a fellowship) from the Association for Supply Chain Management.
分析記事 • Jan 29Sunshine Biopharma, Inc.'s (NASDAQ:SBFM) Share Price Is Matching Sentiment Around Its RevenuesWith a price-to-sales (or "P/S") ratio of 0.3x Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) may be sending very bullish...
Reported Earnings • Nov 15Third quarter 2023 earnings: EPS exceeds analyst expectationsThird quarter 2023 results: US$0.025 loss per share (improved from US$0.077 loss in 3Q 2022). Revenue: US$5.96m (up US$5.82m from 3Q 2022). Net loss: US$651.5k (loss narrowed 55% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 33%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 50% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • Oct 19Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023Sunshine Biopharma, Inc., Annual General Meeting, Dec 07, 2023, at 10:00 US Eastern Standard Time. Agenda: To consider and elect five persons to Board of Directors, until the 2024 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to consider and ratify the appointment of BF Borgers, CPA P.C. as the Company’s independent registered public accountant to audit the Company’s financial books and records for its fiscal year ending December 31, 2023; to consider and approve the Company’s 2023 Equity Incentive Plan.
お知らせ • Sep 23Sunshine Biopharma Receives 180-Day Extension to Achieve Nasdaq Minimum Bid ComplianceSunshine Biopharma Inc. (the "Company") announced that it has received a 180-day extension, until March 18, 2024, to achieve compliance with the Nasdaq $1.00 minimum bid price rule. The Nasdaq staff has determined that Sunshine Biopharma is eligible, based on the Company meeting the continued listing requirements for market value of publicly held shares and all other applicable requirements for initial listing on the Capital Market with the exception of the bid price requirement, and the Company's written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. If at any time before March 18, 2024, the closing bid price of the Company's common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule and this matter will be closed. This current notification from Nasdaq has no immediate effect on the listing or trading of the Company's common stock, which will continue to trade on the Nasdaq Capital Market under the symbol "SBFM".
分析記事 • Sep 12Slammed 26% Sunshine Biopharma, Inc. (NASDAQ:SBFM) Screens Well Here But There Might Be A CatchUnfortunately for some shareholders, the Sunshine Biopharma, Inc. ( NASDAQ:SBFM ) share price has dived 26% in the last...
Reported Earnings • Aug 13Second quarter 2023 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2023 results: US$0.036 loss per share (further deteriorated from US$0.034 loss in 2Q 2022). Revenue: US$5.56m (up US$5.41m from 2Q 2022). Net loss: US$902.1k (loss widened 67% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) also surpassed analyst estimates by 75%. Revenue is forecast to grow 74% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 52% per year, which means it is significantly lagging earnings.
お知らせ • May 17Sunshine Biopharma, Inc. announced that it has received CAD 5 million in fundingOn May 16, 2023, Sunshine Biopharma, Inc. closed the transaction. In connection with the sale of the securities described in Item 1.01, the Company relied upon the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(b) of Regulation D promulgated thereunder for transactions not involving a public offering.
Reported Earnings • May 11First quarter 2023 earnings released: US$0.077 loss per share (vs US$0.23 loss in 1Q 2022)First quarter 2023 results: US$0.077 loss per share. Revenue: US$4.89m (up US$4.77m from 1Q 2022). Net loss: US$1.70m (loss widened 38% from 1Q 2022).
Reported Earnings • Apr 08Full year 2022 earnings released: US$1.76 loss per share (vs US$4.76 loss in FY 2021)Full year 2022 results: US$1.76 loss per share. Revenue: US$4.35m (up US$4.12m from FY 2021). Net loss: US$26.7m (loss widened 115% from FY 2021).
お知らせ • Jan 20Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces an Equity Buyback for $2 million worth of its shares.Sunshine Biopharma, Inc. (NasdaqCM:SBFM) announces a share repurchase program. Under the program, the company will repurchase up to $2 million worth of its shares. As of November 7, 2022, the company had approximately 22,600,000 shares of common stock issued and outstanding.
Reported Earnings • Nov 09Third quarter 2022 earnings released: US$0.077 loss per share (vs US$1.59 loss in 3Q 2021)Third quarter 2022 results: US$0.077 loss per share (improved from US$1.59 loss in 3Q 2021). Net loss: US$1.46m (loss narrowed 64% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 98% per year but the company’s share price has fallen by 33% per year, which means it is significantly lagging earnings.
Seeking Alpha • Oct 20Sunshine Biopharma acquires Nora Pharma for C$30MSunshine Biopharma (NASDAQ:SBFM) said on Thursday it had completed the acquisition of all the outstanding shares of Nora Pharma for C$30M ($21.9M). The acquisition will help Sunshine Biopharma to expand its operations into the area of generic prescription drugs and biosimilars. Nora Pharma currently offers over 50 pharmaceutical products, including generic prescription drugs, over-the-counter products and biosimilars. Nora Pharma will operate as a subsidiary of Sunshine. (SBFM) is down ~4% premarket.
分析記事 • Aug 08We Think Sunshine Biopharma (NASDAQ:SBFM) Can Afford To Drive Business GrowthJust because a business does not make any money, does not mean that the stock will go down. For example, although...
Reported Earnings • Aug 04Second quarter 2022 earnings released: US$0.034 loss per share (vs US$1.20 loss in 2Q 2021)Second quarter 2022 results: US$0.034 loss per share (up from US$1.20 loss in 2Q 2021). Net loss: US$538.9k (loss narrowed 81% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 111% per year but the company’s share price has fallen by 56% per year, which means it is significantly lagging earnings.
Seeking Alpha • Aug 04Sunshine Biopharma reports 1H resultsSunshine Biopharma press release (NASDAQ:SBFM): 1H Revenue of $0.27M. The Company had a net loss of $1,775,106 in the first half of 2022, compared to a net loss of $9,064,180 in the first half of 2021.
Reported Earnings • May 07First quarter 2022 earnings released: US$0.23 loss per share (vs US$2.82 loss in 1Q 2021)First quarter 2022 results: US$0.23 loss per share (up from US$2.82 loss in 1Q 2021). Net loss: US$1.24m (loss narrowed 80% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 118% per year but the company’s share price has fallen by 61% per year, which means it is significantly lagging earnings.
Seeking Alpha • Apr 17Sunshine Biopharma: Advancing Novel Cancer Therapies And Antiviral DrugsSunshine Biopharma is developing novel Topoisomerase II inhibiting cancer therapies and PLpro inhibiting antiviral drugs. The Company has a strong IP backing, although much of it is tied in with the CEO. The Company recently raised $13.6 million in net proceeds from a public offering following a 200:1 reverse split, and a private placement. Note: we do not recommend stocks with such low market caps however attractive they may otherwise sound.
Board Change • Feb 22Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Director Rabi Kiderchah was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 16Sunshine Biopharma Common Stock Deleted from Other OTCSunshine Biopharma, Inc. Common Stock has been deleted from Other OTC effective from February 15, 2022, due to Market Center Change Listed on NASDAQ.
お知らせ • Jun 10Sunshine Biopharma Mice Study for Covid-19 Treatment Progressing as PlannedSunshine Biopharma Inc. confirmed that its COVID-19 mice study currently underway at the University of Georgia is progressing as planned. The study is assessing the efficacy of two protease inhibitors in preventing transgenic mice challenged with SARS-CoV-2 from progressing to illness and death. Should these studies prove successful, the Company plans to file the data with the FDA and request authorization to do testing in actual COVID-19 patients. Sunshine Biopharma’s protease inhibitor treatment is anticipated to be orally available making it possible for the treatment to be in tablet form which can be taken at home. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 3.7 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. Sunshine Biopharma has completed the synthesis of four potential inhibitors of PLpro and subsequently identified a lead compound, SBFM-PL4. On February 1, 2021, Sunshine Biopharma entered into an exclusive license agreement with the University of Georgia for two Anti-Coronavirus compounds which the University of Georgia had previously developed and patented. The Company is currently advancing the development of these two compounds in parallel with its own SBFM-PL4 by conducting a transgenic mice study in collaboration with the University of Georgia, College of Pharmacy. The mice being used in the study have been genetically engineered to express the human angiotensin-converting enzyme 2 (hACE2) transmembrane protein in their lungs making them susceptible to lethal infection by SARS-CoV-2. The SARS-CoV-2 virus uses the hACE2 receptor to gain entry into human cells to replicate. The goal of the study is to determine if these protease inhibitors will protect the hACE2-transgenic mice from disease progression and death following infection with SARS-CoV-2. Should these mice studies prove successful, Sunshine Biopharma plans to submit the results to the FDA for authorization to conduct testing on actual COVID-19 patient volunteers in a Phase I clinical trial setting. In addition, to working on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is owner of all patents and intellectual property pertaining to Adva-27a.
お知らせ • May 26Sunshine Biopharma, Inc.’s Adva-27a Destroys Cancer Cells Expressing P-glycoprotein, a Marker Present in Over 50% of All Cancer TypesSunshine Biopharma Inc. announced that it has elucidated the mechanism of action of Adva-27a, the Company’s flagship anticancer drug candidate. Adva-27a has been found to have two activities: (i) evasion of P-glycoprotein, and (ii) inhibition of Topoisomerase II. P-glycoprotein is the most often encountered transmembrane efflux protein responsible for multidrug resistance in over 50% of all cancer types. By escaping the efflux pump of P-glycoprotein, Adva-27a is able to accumulate inside cancer cells and destroy them by inhibiting Topoisomerase II, a DNA unwinding enzyme preferentially used by cancer cells to multiply. Multidrug resistance is by far the biggest challenge in cancer therapy and P-glycoprotein is the major culprit. A plethora of anticancer drugs that are central to chemotherapeutic regimes are susceptible to the P-glycoprotein efflux activity. Among these are the vinca alkaloids (vinblastine and vincristine), the taxanes (paclitaxel and docetaxel), the anthracyclines (doxorubicin and daunorubicin), the topoisomerase inhibitors (topotecan and etoposide), and the tyrosine kinase inhibitors (dasatinib and gefitinib). Sunshine Biopharma’s P-glycoprotein evading small molecule, Adva-27a, represents an effective alternative to all of these drugs. In addition, it has been recognized that most cancers consist of a heterogeneous population of drug-sensitive and drug-resistant cells. During the course of current chemotherapy regiments, drug-sensitive cells are selectively destroyed and resistant cells become the dominant cancer cell population, leading to recurrence and metastasis. Unlike existing chemotherapy drugs, Adva-27a is able to destroy both populations of cancer cells resulting in more complete eradication of the cancer being treated.
お知らせ • Apr 24Sunshine Biopharma, Inc. announced that it has received $0.5 million in funding from RB Capital Partners, Inc.Sunshine Biopharma, Inc. (OTCPK:SBFM) announced that it has received $500,000 in a round funding from returning investor RB Capital Partners, Inc. on April 22, 2021.
お知らせ • Mar 06Sunshine Biopharma Receives Recently Ordered New Batch of Adva-27a and Initiates QA/QC TestingSunshine Biopharma Inc. announced that it has received shipment of a new batch of Adva-27a from its manufacturer in China. The material has been delivered to the laboratories of Sunshine Biopharma’s drug development partner in Montreal (Canada). Following initial QA/QC testing of the material for specific biological activity, Sunshine Biopharma will proceed to performing tumor inhibition studies on xenograft mice harboring tumors of human pancreatic cancer origin. Pancreatic Cancer is Sunshine Biopharma’s clinical trials indication for Adva-27a. Among several other cancer types, Pancreatic Cancer is resistant to existing chemotherapy drugs but has been shown to be susceptible to Adva-27a in preclinical studies.
お知らせ • Aug 15Sunshine Biopharma, Inc. announced delayed 10-Q filingOn 08/14/2020, Sunshine Biopharma, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.